Lantheus Holdings, Inc.
LNTH
주식 순위
#2846
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the... Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
주가
$100.28
시가총액
$6.55B
변동 (1일)
0.36%
변동 (1년)
77.16%
국가
US
거래 Lantheus Holdings, Inc. (LNTH)
카테고리
Healthcare
Lantheus Holdings, Inc. (LNTH)의 매출
Jun 2026 기준 매출 TTM: $1.56B
Lantheus Holdings, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $1.56B입니다. 2023년에 회사는 $1.30B의 수익을 올렸으며 이는 2022년의 $935.06M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Lantheus Holdings, Inc.의 수익 기록 (2011 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.56B | 1.46% |
| 2024 | $1.53B | 18.32% |
| 2023 | $1.30B | 38.65% |
| 2022 | $935.06M | 119.91% |
| 2021 | $425.21M | 25.28% |
| 2020 | $339.41M | -2.28% |
| 2019 | $347.34M | 1.15% |
| 2018 | $343.37M | 3.62% |
| 2017 | $331.38M | 9.78% |
| 2016 | $301.85M | 2.86% |
| 2015 | $293.46M | -2.70% |
| 2014 | $301.60M | 6.32% |
| 2013 | $283.67M | -1.54% |
| 2012 | $288.11M | -19.14% |
| 2011 | $356.29M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 324.83% |
IN
|
